News
AXSM
71.52
+0.49%
0.35
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences, Inc. Achieved positive results from its phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with major depressive disorder. The drug may offer several advantages over existing treatment options. The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032. Neurocrine has already received FDA approval for a drug for Huntington's Disease. The company has several catalysts to look forward to.
Seeking Alpha · 11h ago
Neurocrine Biosciences upgraded at Wells Fargo on pipeline
Wells Fargo upgraded Neurocrine Biosciences from equal weight to overweight on the strength of its pipeline. The firm also upped its price target to $170 from $140. Analyst believes the company's crinecerfont could be a $1.5B drug.
Seeking Alpha · 1d ago
Weekly Report: what happened at AXSM last week (0415-0419)?
Weekly Report · 3d ago
Strong Buy on Axsome’s Auvelity Amidst Competitive MDD Market
TipRanks · 04/18 05:07
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Intra-Cellular Therapies, Inc. Just reported positive results from one of its phase 3 studies using lumateperone as an adjunctive therapy for the treatment of patients with major depressive disorder. The Major Depressive Disorder market across the eight major markets is expected to reach $9.6 billion by 2029. The company has already received FDA approval of its drug Caplyta.
Seeking Alpha · 04/16 17:17
Auvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeutics
TipRanks · 04/16 06:56
AXSOME THERAPEUTICS INC - NEW DATA FOR AXS-07 IN MIGRAINE DEMONSTRATING EFFICACY IN POOLED ANALYSIS
Reuters · 04/15 11:02
Weekly Report: what happened at AXSM last week (0408-0412)?
Weekly Report · 04/15 10:49
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Barchart · 04/15 06:00
AXSM Quantitative Stock Analysis
NASDAQ · 04/13 19:06
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
NASDAQ · 04/11 14:15
Analyst Ratings For Axsome Therapeutics
20 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM) in the last three months. The 12-month price targets assessed by analysts have an average target of $130.3. The company is developing novel therapies for the management of central nervous system disorders.
Benzinga · 04/10 16:00
ClearBridge Small Cap Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Small Cap Strategy underperformed the benchmark Russell 2000 Index in the first quarter by 177 bps. The two largest-capitalization stocks in the index - Super Micro Computer and MicroStrategy - contributed to the index's performance. Super Micro is now the largest position ever in the Russell 2000 index.
Seeking Alpha · 04/10 14:40
Axsome Therapeutics Price Target Maintained With a $107.00/Share by Cantor Fitzgerald
Dow Jones · 04/10 13:45
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Benzinga · 04/10 13:35
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)
TipRanks · 04/10 06:21
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Axsome Therapeutics, Inc. Will report its financial results for the first quarter of 2024 on May 6, 2024. Axsome is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders. The company will host a conference call to discuss these results.
Barchart · 04/10 06:00
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanks · 04/09 02:10
Weekly Report: what happened at AXSM last week (0401-0405)?
Weekly Report · 04/08 10:53
Axsome Therapeutics Price Target Maintained With a $190.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 13:03
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.